Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

Heterogeneity of SSTR2 Expression Assessed by 68Ga-DOTATOC PET/CT Using Coefficient of Variation in Patients with Neuroendocrine Tumors

Rosa Fonti, Mariarosaria Panico, Sara Pellegrino, Alessandro Pulcrano, Luisa Alessia Vastarella, Armin Hakkak Moghadam Torbati, Mario Giuliano, Giovannella Palmieri, Sabino De Placido and Silvana Del Vecchio
Journal of Nuclear Medicine October 2022, 63 (10) 1509-1514; DOI: https://doi.org/10.2967/jnumed.121.262928
Rosa Fonti
1Institute of Biostructures and Bioimages, National Research Council, Naples, Italy;
2Department of Advanced Biomedical Sciences, University of Naples “Federico II,” Naples, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariarosaria Panico
1Institute of Biostructures and Bioimages, National Research Council, Naples, Italy;
2Department of Advanced Biomedical Sciences, University of Naples “Federico II,” Naples, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Pellegrino
2Department of Advanced Biomedical Sciences, University of Naples “Federico II,” Naples, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessandro Pulcrano
2Department of Advanced Biomedical Sciences, University of Naples “Federico II,” Naples, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luisa Alessia Vastarella
2Department of Advanced Biomedical Sciences, University of Naples “Federico II,” Naples, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Armin Hakkak Moghadam Torbati
2Department of Advanced Biomedical Sciences, University of Naples “Federico II,” Naples, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mario Giuliano
3Department of Clinical Medicine and Surgery, University of Naples “Federico II,” Naples, Italy; and
4CRCTR Coordinating Rare Tumors Reference Center of Campania Region, AOU “Federico II,” Naples, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giovannella Palmieri
4CRCTR Coordinating Rare Tumors Reference Center of Campania Region, AOU “Federico II,” Naples, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabino De Placido
3Department of Clinical Medicine and Surgery, University of Naples “Federico II,” Naples, Italy; and
4CRCTR Coordinating Rare Tumors Reference Center of Campania Region, AOU “Federico II,” Naples, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Silvana Del Vecchio
2Department of Advanced Biomedical Sciences, University of Naples “Federico II,” Naples, Italy;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Visual Abstract

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Abstract

High levels of somatostatin receptor subtype 2 (SSTR2) are a prerequisite for therapy with unlabeled or labeled somatostatin analogs. However, it is still unclear how the heterogeneity of SSTR2 expression may affect tumor response to therapy. The aim of our study was to test the ability of an imaging parameter such as coefficient of variation (CoV) derived from PET/CT with 68Ga-peptides in the evaluation and quantification of the heterogeneity of SSTR2 expression within primary and metastatic lesions of patients with neuroendocrine tumors. Methods: Thirty-eight patients with pathologically proven neuroendocrine tumors who underwent 68Ga-DOTATOC PET/CT were studied. Primary tumors were localized in the gastroenteropancreatic, bronchopulmonary, and other anatomic districts in 25, 7, and 6 patients, respectively. Malignant lesions were segmented using an automated contouring program and an SUV threshold of more than 2.5 or, in the case of liver lesions, a threshold of 30% of the SUVmax. The imaging parameters SUVmean, CoV, SUVmax, receptor-expressing tumor volume, and total lesion receptor expression were obtained for each lesion. SUVmean, CoV, and SUVmax were also obtained for representative volumes of normal liver and spleen, as well as for the whole pituitary gland. Results: In total, 107 lesions were analyzed, including 35 primary tumors, 32 metastatic lymph nodes, and 40 distant metastases. Average CoVs were 0.49 ± 0.20 for primary tumors, 0.57 ± 0.26 for lymph node metastases, and 0.44 ± 0.20 for distant metastases. The CoVs of malignant lesions were up to 4-fold higher than those of normal tissues (P ≤ 0.0001). Among malignant lesions, the highest CoV was found for bone metastases (0.68 ± 0.20), and it was significantly greater than that of primary lesions (P = 0.01) and liver metastases (P < 0.0001). On the other hand, the lowest CoV was found for liver lesions (0.32 ± 0.07), probably because of the high background uptake. Conclusion: Our findings indicate that the heterogeneity of uptake, reflecting that of SSTR2, varies with the type and site of malignant lesions as assessed by CoVs obtained from 68Ga-DOTATOC PET/CT scans. These observations may be related to different biologic characteristics of tumor lesions in the same patient—differences that may affect their response to treatment with both labeled and unlabeled somatostatin analogs.

  • somatostatin receptor 2
  • heterogeneity
  • coefficient of variation
  • 68Ga-peptide PET/CT
  • neuroendocrine tumors

Footnotes

  • Published online Mar. 10, 2022.

  • © 2022 by the Society of Nuclear Medicine and Molecular Imaging.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 63 (10)
Journal of Nuclear Medicine
Vol. 63, Issue 10
October 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Heterogeneity of SSTR2 Expression Assessed by 68Ga-DOTATOC PET/CT Using Coefficient of Variation in Patients with Neuroendocrine Tumors
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Heterogeneity of SSTR2 Expression Assessed by 68Ga-DOTATOC PET/CT Using Coefficient of Variation in Patients with Neuroendocrine Tumors
Rosa Fonti, Mariarosaria Panico, Sara Pellegrino, Alessandro Pulcrano, Luisa Alessia Vastarella, Armin Hakkak Moghadam Torbati, Mario Giuliano, Giovannella Palmieri, Sabino De Placido, Silvana Del Vecchio
Journal of Nuclear Medicine Oct 2022, 63 (10) 1509-1514; DOI: 10.2967/jnumed.121.262928

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Heterogeneity of SSTR2 Expression Assessed by 68Ga-DOTATOC PET/CT Using Coefficient of Variation in Patients with Neuroendocrine Tumors
Rosa Fonti, Mariarosaria Panico, Sara Pellegrino, Alessandro Pulcrano, Luisa Alessia Vastarella, Armin Hakkak Moghadam Torbati, Mario Giuliano, Giovannella Palmieri, Sabino De Placido, Silvana Del Vecchio
Journal of Nuclear Medicine Oct 2022, 63 (10) 1509-1514; DOI: 10.2967/jnumed.121.262928
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • 177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy
  • Adverse Clinical Events at the Injection Site Are Exceedingly Rare After Reported Radiopharmaceutical Extravasation in Patients Undergoing 99mTc-MDP Whole-Body Bone Scintigraphy: A 12-Year Experience
  • The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [18F]MK6240 Tau PET in Target Regions
Show more Clinical Investigation

Similar Articles

Keywords

  • somatostatin receptor 2
  • heterogeneity
  • coefficient of variation
  • 68Ga-peptide PET/CT
  • neuroendocrine tumors
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire